Leukaemia Trial, Recruiting (NCT06874257)

Leukaemia Trial, Recruiting NCT06874257 Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06874257 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 years or older who have been newly diagnosed with a type of blood cancer called Acute Myeloid Leukaemia (AML), based on 2022 World Health Organization diagnostic standards
People whose doctor has determined they are not suitable for strong, intensive chemotherapy
People who are being treated with two specific medications — azacitidine and venetoclax — as their first-line treatment, as part of their normal care
People who have given signed written consent to participate in the trial
Healthy volunteers aged 18 or older who have given signed written consent to participate (as donors for comparison purposes)

Who may not be able to join:

People who have a specific subtype of AML called acute promyelocytic leukaemia
People whose AML has spread to the central nervous system (the brain and spinal cord)
People who have not yet started treatment with azacitidine and venetoclax

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Antonio Curti, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phone: +39 0512144074

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06874257

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: +39 0512144074

More information: https://clinicaltrials.gov/study/NCT06874257

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 years or older who have been newly diagnosed with a type of blood cancer called Acute Myeloid Leukaemia (AML), based on 2022 World Health Organization diagnostic standards
People whose doctor has determined they are not suitable for strong, intensive chemotherapy
People who are being treated with two specific medications — azacitidine and venetoclax — as their first-line treatment, as part of their normal care
People who have given signed written consent to participate in the trial
Healthy volunteers aged 18 or older who have given signed written consent to participate (as donors for comparison purposes)

Who may not be able to join:

People who have a specific subtype of AML called acute promyelocytic leukaemia
People whose AML has spread to the central nervous system (the brain and spinal cord)
People who have not yet started treatment with azacitidine and venetoclax

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Registry

ClinicalTrials.gov

Start date

17 April 2024

Est. completion

31 October 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Pan-tissue AHR signature; IFN-y pathway response; Immunometabolic shift in T-cells; Clinical response; Survival (Aim 4)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov